+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07251595

Phase 2 Clinical Study of SHR0302 Tablets Alone or With SHR0302 Base Gel to Treat Non-segmental Vitiligo

Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-02-18

176

Participants Needed

1

Research Sites

26 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of SHR0302 tablets alone or combined with SHR0302 Base gel for treating patients with non-segmental vitiligo. This randomized, double-blind, placebo-controlled Phase II trial aims to better understand how these treatments impact vitiligo, a condition causing skin depigmentation. The study is sponsored by Jiangsu HengRui Medicine Co., Ltd. and includes adult patients between 18 and 75 years old. Participants are assigned to one of four groups low-dose SHR0302 tablets, high-dose SHR0302 tablets, SHR0302 tablets combined with SHR0302 Base gel, or placebo tablets with placebo gel. The treatments are given according to the assigned group, and the study monitors patients for up to 48 weeks to assess changes in vitiligo symptoms and quality of life. During the trial, participants will have regular evaluations including measuring the percentage change in facial vitiligo area score index at 24 weeks as the primary outcome. Secondary outcomes include changes in total body vitiligo area, physician assessments, quality of life measures, and blood tests for drug levels and immune markers. Safety and effectiveness will be carefully monitored throughout the study until its completion in September 2027.

CONDITIONS

Brief Title

A Trial of SHR0302 Tablets and SHR0302 Base Gel in Patients With Non-segmental Vitiligo

Research Team

H

Hui Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here